[Value of chemotherapy preceding exclusive conservative loco-regional radiotherapy in breast cancer].
Baillet
F
F
Centre des Tumeurs, Hôpital Pitié-Salpêtrière, Paris, France.
Housset
M
M
Khayat
D
D
Rozec
C
C
Ucla
L
L
Maulard
C
C
Brunel
P
P
Hu
B Q
BQ
Delanian
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D011829:Radiation Dosage; D013852:Thiotepa / Q000627:therapeutic use*; D014747:Vinblastine / Q000627:therapeutic use*
D014747:Vinblastine; D004317:Doxorubicin; D013852:Thiotepa; D005472:Fluorouracil; D008727:Methotrexate
Intérêt de la chimiothérapie première pour le traitement loco-régional conservateur du cancer du sein par radiothérapie exclusive.